Skip to content

A Study of the Combination of Electrical Stimulation and Dysport® in Myofascial Pain Syndrome.

A 16-week Prospective Randomised Double-blind Study on Facilitation of DYSPORT® Effect on Myofascial Pain Syndrome (MPS) by Electrical Stimulation.

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00246142
Enrollment
76
Registered
2005-10-31
Start date
2005-04-30
Completion date
2007-06-27
Last updated
2019-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myofascial Pain Syndromes

Brief summary

The purpose of this study is to determine whether electrical stimulation enhances the effect of botulinum toxin type A (Dysport®) on myofascial pain syndrome.

Interventions

BIOLOGICALBotulinum toxin type A

Sponsors

Ipsen
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE

Eligibility

Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Chronic neck and shoulder pain for at least 6 months, refractory with other conservative treatments * Presents at baseline with pain score greater than 50mm on 100mm length VAS. Pain score will be measured as overall pain over the 7 days preceding the visit during activities * Active trigger point (TrP) defined as a tender spot localised in a taut band of muscle fibres associated with tenderness AND referred pain recognised by the patient into well-defined areas that are remote from the TrP area at palpation AND preferably local twitch response at palpation AND/OR jump sign at palpation

Exclusion criteria

* Disc/bone disease * History of surgery on neck * Neurological deficits, neuromuscular junction disorder, Motor Neuron disease * Patient has received anesthetic injections to the target trigger point within 4 weeks of study enrolment, or corticosteroid injections within 3 months * Systemic inflammatory disease * Hypersensitivity to Dysport® * Diffuse tender points, or diagnosed with fibromyalgia * Previous electrical stimulation * Previous injection of Dysport® within 6 months of study enrolment

Design outcomes

Primary

MeasureTime frame
Changes in mean pain measured by Visual Analogue Scale (VAS) will be assessed.Comparison of VAS will be performed before Dysport® injection and at 16 weeks after injection
Number of patients in percentage whose pain intensity measured by VAS decreases to less than 50% of baseline.Before Dysport® injection and at 16 weeks after injection

Secondary

MeasureTime frame
Pain threshold measured by pressure algometer.At each visit
Neck Pain and Disability scale (NPAD) and Global Assessment of Impairment Scale (GAS) will be assessed.At each visit

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026